Citizens analyst Jonathan Wolleben last night downgraded Quince Therapeutics (QNCX) to Market Perform from Outperform without a price target The firm cites the dexamethasone sodium phosphate encapsulated in autologous erythrocytes miss in the Phase 3 NEAT trial for the downgrade. The analyst expects the shares to trade near or below it cash levels as management explores its available options.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNCX:
- Quince Therapeutics downgraded to Market Perform from Outperform at Citizens
- Quince Therapeutics down 88% after reopening for trading
- Quince Therapeutics trading resumes
- Quince down 14% after NEAT study endpoint did not reach statistical significance
- Quince Therapeutics to cease clinical development of eDSP